Detalhe da pesquisa
1.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Am J Hematol
; 95(2): 178-187, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821591
2.
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Biomedicines
; 9(6)2021 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34200749
3.
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
Mol Cancer Ther
; 7(8): 2288-97, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18723476
4.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Neurology
; 92(23): e2661-e2673, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118245
5.
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
J Clin Invest
; 128(10): 4372-4386, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30040076
6.
Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.
Front Immunol
; 8: 867, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28824615
7.
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Clin Cancer Res
; 23(21): 6411-6420, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28765328
8.
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Cancer Immun
; 6: 4, 2006 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-16483188
9.
Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.
Protein Eng Des Sel
; 29(4): 123-33, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26945588
10.
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Cancer Res
; 75(16): 3373-83, 2015 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26141862
11.
Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.
J Cancer Res Clin Oncol
; 129(6): 341-8, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12819960
12.
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
MAbs
; 6(2): 523-32, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24492296
13.
Four individually druggable MET hotspots mediate HGF-driven tumor progression.
J Clin Invest
; 124(7): 3172-86, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24865428
14.
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Cancer Immunol Immunother
; 55(5): 503-14, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16032400
15.
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
Arthritis Rheum
; 54(6): 1856-66, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16736523
16.
Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo.
Int Immunol
; 15(7): 789-96, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12807817
17.
Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Int J Cancer
; 105(2): 241-8, 2003 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-12673686
18.
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
J Immunol
; 170(8): 4397-402, 2003 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12682277
19.
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Int J Cancer
; 100(6): 690-7, 2002 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-12209608
20.
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Int J Cancer
; 100(1): 101-10, 2002 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12115595